Mechanistic gaps in alopecia areata

Advances in understanding JAK–STAT signaling have transformed treatment for alopecia areata (AA), while growing interest in TEC family kinases is expanding insight into disease biology and informing targeted therapies

AA is a chronic immune-mediated disease with a relapsing, unpredictable clinical course.¹ The Janus kinase–signal transducer and activator of transcription (JAK–STAT) pathway is an established therapeutic target, but growing evidence highlights the role of tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases in disease pathophysiology and treatment.^2,3

As targeted therapies advance, important questions remain: How do individual TEC family kinases contribute to disease pathogenesis? What is the therapeutic value of dual JAK3–TEC inhibition? And will preclinical findings translate into clinically meaningful outcomes?

What role do TEC family kinases play in the pathophysiology of alopecia areata?

TEC family kinases, including TEC, Bruton tyrosine kinase (BTK), and interleukin-2-inducible T-cell kinase (ITK), regulate signaling pathways involved in the activation and function of multiple immune cell populations implicated in AA.^2,3 ITK plays a key role in T-cell receptor signaling and T-cell activation, while BTK is involved in B-cell receptor signaling and the regulation of innate immune responses.^2,3 Together with TEC, these kinases contribute to the inflammatory processes that drive loss of hair follicle immune privilege and promote autoimmune attack on the hair follicle.^2,3 As a result, TEC family kinases are increasingly recognized as potential therapeutic targets in AA, although their biology remains less well characterized than the JAK–STAT pathway.^2,3

How does TEC kinase signaling differ from JAK–STAT signaling in alopecia areata?

In AA, JAK–STAT signaling primarily drives cytokine-mediated inflammation, whereas TEC kinases regulate T-cell activation and effector function.^2-4 Understanding both pathways may help clinicians interpret the mechanism of emerging dual JAK3–TEC inhibitors.^2,3

What is the mechanistic rationale for dual JAK3–TEC pathway inhibition in alopecia areata?

The rationale for dual JAK3–TEC pathway inhibition is based on the complementary roles these signaling pathways play in the immune dysregulation underlying AA. JAK3-mediated signaling is involved in the activity of cytokines that drive inflammatory responses, while TEC family kinases regulate the activation and function of immune cells, including T cells and other leukocyte populations implicated in autoimmune disease.^2-5 Together, these pathways contribute to hair follicle immune privilege collapse and the persistence of autoimmune activity in AA.^2-5 Targeting both pathways may therefore modulate multiple components of the pathogenic immune response, providing a broader mechanistic approach than inhibition of a single signaling pathway alone.^2-5

What challenges do clinicians face when evaluating emerging targeted therapies for alopecia areata?

Key challenges clinicians face when evaluating emerging targeted therapies for alopecia areata center on the uncertainty around how therapies may fit into clinical practice, including which patients are most likely to benefit, how they should be monitored, and where they may fit within existing treatment pathways.^6,7 These challenges are compounded by disease heterogeneity and a limited understanding of newer immune signaling pathways beyond JAK–STAT.^2,6,7 A deeper understanding of the mechanisms underlying emerging therapies, including the role of TEC family kinases, may help clinicians interpret evolving evidence and inform decisions around treatment positioning, sequencing, and patient selection.

What are the limitations of current outcomes-focused approaches in alopecia areata?

Current outcomes-focused approaches to evaluating therapies for alopecia areata are limited by their emphasis on clinical endpoints, such as hair regrowth and Severity of Alopecia Tool (SALT) scores, with insufficient focus on intracellular signaling and broader patient impact.^6-9

Key limitations include:

• Predominant focus on hair regrowth, SALT scores, and safety^6-9
• Limited depth on intracellular signaling mechanisms^2,3
• Incomplete integration of psychosocial burden and comorbidities^3,6-9

As the therapeutic landscape evolves, there is increasing interest in complementing clinical outcome measures with a deeper understanding of disease mechanisms and the broader factors that influence treatment decisions and patient experience.

Key takeaways

• While JAK–STAT signaling is well established, TEC family kinases have emerged as an area of growing research interest^2,3
• Understanding the interaction between JAK and TEC pathways may help explain the rationale for emerging therapeutic approaches^2,3
• Variability in disease presentation and progression can influence how clinical trial findings are applied to individual patients^1,6,7
• Interpretation of new therapies should be considered alongside disease burden, patient characteristics, and treatment goals^2,3

References

1. Lai, 2025. Immune therapies for alopecia areata: Evidence and new perspectives. https://www.doi.org/10.1080/1744666X.2025.2575365
2. Šutić Udović, 2024. Deciphering the complex immunopathogenesis of alopecia areata (abstract). https://www.doi.org/10.3390/ijms25115652
3. An, 2024. A review of TEC family kinases and their inhibitors in the treatment of alopecia areata. https://www.doi.org/10.1007/s00403-024-03229-0
4. Lejeune, 2025. 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo (abstract). https://www.doi.org/10.1016/j.jaad.2025.05.242
5. Ramírez-Marín, 2022. Evaluating the therapeutic potential of ritlecitinib for the treatment of alopecia areata. https://www.doi.org/10.2147/dddt.S334727
6. Mesinkovska, 2023. The invisible impact of a visible disease: Psychosocial impact of alopecia areata. https://www.doi.org/10.1007/s13555-023-00941-z
7. King, 2022. Defining severity in alopecia areata: Current perspectives and a multidimensional framework. https://www.doi.org/10.1007/s13555-022-00711-3
8. Gauthier, 2025. Perceived stigma among adults with alopecia areata in the United States. https://www.doi.org/10.1111/1346-8138.17786
9. Mostaghimi, 2024. Immune-mediated and psychiatric comorbidities among patients newly diagnosed with alopecia areata. https://www.doi.org/10.1001/jamadermatol.2024.2404

Developed by EPG Health for Medthority, independently of any sponsor.